

Publications auxquelles l'Aretasc a participé en 2018

Role of deficient DNA Mismatch repair status in patients treated with stage III colon cancer treated with Folfox adjuvant chemotherapy. A pooled analysis from 2 randomized clinical trials.
Aziz Z. ; Qian S ; Taieb J et al. *Jama oncol.*2018 ;4(3) :379-383.

Etude Ago-Ovar 2.21

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs carboplatin /pegylated liposomal doxorubicin /bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. *Esmo* 2018

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

[Eur J Cancer](#). 2018 Sep 26;103:184-194.doi:10.1016/j.ejca.2018.06.025.
[Epub ahead of print Campone M &al.

A French observational study of Nivolumab-treated lung cancer patients in a real – world setting : Initial results on 1394 advanced non small cell lung cancer patients. *Evidens trial*.
Abst. 1469P ; *Esmo* , 20 octob.2018.

« *PHARE : study randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer* » 5 décembre 2018 en session plénière au San Antonio Breast Cancer Symposium (SABCS)